ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2494

Abatacept Reduces CD319+ (SLAM-F7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis
Abstract Number: 1124

ABCG2 Variants as Genetic Risk Factors for Hyperuricemia and Gout: Focus on Pediatric and Familial Manifestations
Abstract Number: 0097

Aberrant histone marks increase the inflammatory phenotype of rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) by suppressing NUB1 induction
Abstract Number: 1655

Aberrant Noncoding RNAs Are Enriched in Extracellular Vesicles and Implicated in Interferon Activation
Abstract Number: 1022

Abuse in Rheumatic Diseases: Associations with Depression, Disability, and Psychosocial Risk Factors
Abstract Number: 1861

Accelerated and Gene-Specific Patterns of Clonal Hematopoiesis Distinguish Subtypes of Systemic Sclerosis
Abstract Number: 2570

Accelerometer-derived ‘weekend warrior’ physical activity, genetic susceptibility, and incident rheumatoid arthritis: a prospective cohort study
Abstract Number: 1007

Accelerometry-Derived Activity and Sleep Patterns in the NIH All of Us Cohort: Insights and Predictive Potential for Inflammatory Arthritis
Abstract Number: 1084

Access to rheumatology care in patients with new diagnosis of polymyalgia rheumatica: analysis from a national inception cohort
Abstract Number: 0645

Achievement of Low Disease Activity and Remission in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Abstract Number: 2445

Achievement of Treat to Target Measures With Upadacitinib in Patients With Systemic Lupus Erythematosus: Phase 2 Randomized SLEek Clinical Trial Results
Abstract Number: 1349

Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-To-Severe Rheumatoid Arthritis in a Real-World Setting: Final 2-year Outcomes from the UPHOLD Study
Abstract Number: 1531

Achieving Remission and Low Disease Activity with Belimumab Versus Placebo in Patients with SLE Excluding the Glucocorticoid Component from Target Definitions: A Post Hoc Analysis of Five Phase 3 Trials
Abstract Number: 0801

Achieving Sustained Lupus Low Disease Activity State and Remission With Ianalumab (VAY736) in Patients with Systemic Lupus Erythematosus: A post hoc Analysis From a Phase II Study
Abstract Number: 2270

ACKR1 and Leukopenia in Patients with Rheumatoid Arthritis Treated with Disease Modifying Antirheumatic Drugs

« Previous Page
1
…
5
6
7
8
9
…
182
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].